Skip to main content

JAK/TYK2

      Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.  Many people missed the last day (June 3rd) of the meeting as a pending Milan airport strike on June 4th dictated last-minute changes to travel and learning. Here are a few of my favorite abstracts from the Late Breaker Session.
      An update on JAK inhibitors and cardiovascular risks

      Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments

      Dr. John Cush RheumNow

      2 years ago
      An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
      Upadacitinib in SLE
      RT @bella_mehta: JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA

      Bella Mehta bella_mehta

      2 years ago
      JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
      RT @bella_mehta: Abstracts talking about #RA and JAKs and Biologic comparisons
      Huge number of pts to analyze this aftrr

      Bella Mehta bella_mehta

      2 years ago
      Abstracts talking about #RA and JAKs and Biologic comparisons Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below @RheumNow https://t.co/jl5S4fLq19
      RT @bella_mehta: #EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
      - 3 more drugs now available

      Bella Mehta bella_mehta

      2 years ago
      #EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i
      RT @drdavidliew: Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL S

      David Liew drdavidliew

      2 years ago
      Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY
      RT @drdavidliew: Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform exist

      David Liew drdavidliew

      2 years ago
      Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing. We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8
      RT @Janetbirdope: What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JA

      Janet Pope Janetbirdope

      2 years ago
      What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
      JAKpot or JAKnot
      ×